Unicycive Therapeutics Inc (Nasdaq:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced on Monday that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 28 June 2025. If approved, OLC could offer a more convenient treatment option for CKD patients with hyperphosphatemia, requiring fewer pills per dose and easier administration.
The NDA submission is based on data from clinical and preclinical studies, as well as chemistry, manufacturing and controls data.
Unicycive is preparing for a potential commercial launch of OLC in the second half of 2025.
Endo signs definitive agreement for Paladin Pharma to commercialise Wynzora Cream in Canada
Merck's KEYTRUDA plus chemotherapy receives positive EU opinion for first-line MPM treatment
Sanofi seeks FDA approval for Dupixent in chronic spontaneous urticaria
Azurity Pharmaceuticals' Danziten granted US FDA approval
PTC Therapeutics' gene therapy to treat AADC deficiency receives US FDA accelerated approval
Caliway Biopharmaceuticals' CBL-514 receives EMA Orphan Drug Designation
Jubilant Radiopharma forms collaboration with Simplified Imaging Solutions
Eupraxia Pharmaceuticals reveals additional data from RESOLVE Phase 1b/2a trial of EP-104GI